Primary Open Angle Glaucoma (POAG) Market
Key Highlights
- As per DelveInsight, the Primary Open Angle Glaucoma (POAG) Market is expected to expand at a healthy growth rate during the forecast period (2023-2032), owing to the launch of new therapies in the market and the rise in the number of cases.
- Several major pharma and biotech companies such as Santen Pharmaceutical Co., Ltd., PH PHARMA CO. LTD., Whitecap Biosciences, LLC, Ocular Therapeutix, Inc., and TheratOcular Biotek Co., Ltd., among others, are actively working in the Primary Open Angle Glaucoma (POAG) Market.
Download the Sample PDF to Get More Insight @ Primary Open Angle Glaucoma (POAG) Market
DelveInsight's "Primary Open Angle Glaucoma (POAG) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Primary Open Angle Glaucoma (POAG), historical and forecasted epidemiology as well as the Primary Open Angle Glaucoma (POAG) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Primary Open Angle Glaucoma (POAG) market report provides current treatment practices, emerging drugs, Primary Open Angle Glaucoma (POAG) market share of the individual therapies, current and forecasted Primary Open Angle Glaucoma (POAG) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Primary Open Angle Glaucoma (POAG) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Primary Open Angle Glaucoma (POAG) market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Primary Open Angle Glaucoma (POAG) Disease Understanding and Treatment Algorithm
Primary open-angle glaucoma (POAG) is a chronic and progressive eye condition characterized by increased intraocular pressure (IOP) that damages the optic nerve, leading to vision loss and potential blindness if left untreated. It's the most common type of glaucoma, often developing gradually and painlessly, and typically goes unnoticed until advanced stages when peripheral vision is affected.
The precise cause of POAG is not fully understood, but it's often linked to a buildup of aqueous humor, the fluid that maintains eye pressure. Risk factors include age (more common in individuals over 60), family history of glaucoma, African or Hispanic ancestry, certain medical conditions like high blood pressure or diabetes, and specific eye conditions or previous eye injuries.
Primary Open-angle Glaucoma Signs and Symptoms
Primary Open-angle Glaucoma is often asymptomatic in its early stages, earning it the nickname "the silent thief of sight." As the condition progresses, individuals may experience gradual peripheral vision loss, leading to tunnel vision. Other symptoms can include patchy blind spots in the peripheral or central vision, blurred vision, and in advanced cases, severe eye pain, nausea, or vomiting.
Primary Open-angle Glaucoma Diagnosis
Diagnosing Primary Open-angle Glaucoma involves comprehensive eye examinations, including measurement of intraocular pressure, assessment of the optic nerve using a specialized instrument called an ophthalmoscope, visual field tests to check for peripheral vision loss and evaluation of the cornea's thickness (corneal pachymetry). These tests help in confirming the diagnosis and assessing the severity of the condition.
Treatment Options in the Primary Open-angle Glaucoma Therapeutics Market
The primary goal of POAG treatment is to lower intraocular pressure to prevent further damage to the optic nerve. Treatment may include eye drops (prostaglandin analogs, beta-blockers, alpha agonists, or carbonic anhydrase inhibitors) to reduce IOP, laser therapy (laser trabeculoplasty) to improve fluid drainage from the eye, or surgical procedures (trabeculectomy or shunt implantation) to create new drainage pathways.
Primary Open Angle Glaucoma (POAG) Epidemiology
The Primary Open Angle Glaucoma (POAG) epidemiology section provides insights into the historical and current Primary Open Angle Glaucoma (POAG) patient pool and forecasted trends for seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Primary Open Angle Glaucoma (POAG) market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Primary Open Angle Glaucoma (POAG) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Primary Open Angle Glaucoma (POAG) Epidemiology
The epidemiology segment also provides the Primary Open Angle Glaucoma (POAG) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Get detailed insights into the historical as well as forecasted epidemiology trends in the 7MM, at: Primary Open Angle Glaucoma (POAG) Epidemiology Forecast
Primary Open Angle Glaucoma (POAG) Drug Chapters
The drug chapter segment of the Primary Open Angle Glaucoma (POAG) report encloses the detailed analysis of Primary Open Angle Glaucoma (POAG) marketed drugs and late-stage (Phase-III and Phase-II) Primary Open Angle Glaucoma (POAG) pipeline drugs. It also helps to understand the Primary Open Angle Glaucoma (POAG) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Primary Open Angle Glaucoma (POAG) Marketed Drugs
The report provides the details of the marketed products/off-label treatments available for Primary Open Angle Glaucoma (POAG) treatment.
Primary Open Angle Glaucoma (POAG) Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Primary Open Angle Glaucoma (POAG) treatment.
Primary Open Angle Glaucoma (POAG) Market Outlook
The Primary Open Angle Glaucoma (POAG) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Primary Open Angle Glaucoma (POAG) market trends by analyzing the impact of current Primary Open Angle Glaucoma (POAG) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Primary Open Angle Glaucoma (POAG) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Primary Open Angle Glaucoma (POAG) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Primary Open Angle Glaucoma (POAG) market in the 7MM is expected to witness a major change in the study period 2019-2032.
Key Findings
This section includes a glimpse of the Primary Open Angle Glaucoma (POAG) market in 7MM.
The United States Market Outlook
This section provides the total Primary Open Angle Glaucoma (POAG) market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Primary Open Angle Glaucoma (POAG) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Primary Open Angle Glaucoma (POAG) market size and market size by therapies in Japan is also mentioned.
Primary Open Angle Glaucoma (POAG) Drugs Uptake
This section focuses on the rate of uptake of the Primary Open Angle Glaucoma (POAG) drugs recently launched in the Primary Open Angle Glaucoma (POAG) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Primary Open Angle Glaucoma (POAG) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Primary Open Angle Glaucoma (POAG) drug uptake helps in understanding the drugs with the most rapid uptake, and the reasons behind the maximal use of new drugs, and allows the comparison of the drugs on the basis of Primary Open Angle Glaucoma (POAG) market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Primary Open Angle Glaucoma (POAG) Pipeline Development Activities
The Primary Open Angle Glaucoma (POAG) report provides insights into different therapeutic candidates in Phase II and Phase III stages. It also analyses Primary Open Angle Glaucoma (POAG) key players involved in developing targeted therapeutics.
Pipeline Development Activities
The Primary Open Angle Glaucoma (POAG) report covers detailed information of collaborations, acquisitions, and mergers, licensing, patent details, and other information for Primary Open Angle Glaucoma (POAG) emerging therapies.
Explore more about the emerging therapies and key companies actively working in the market: Primary Open Angle Glaucoma (POAG) Pipeline Insight
Primary Open-Angle Glaucoma Market Growth Factors
The market for Primary Open-angle Glaucoma treatment is influenced by various factors. Technological advancements in diagnostic tools and imaging techniques for early detection and monitoring of glaucoma drive market growth. Pharmaceutical companies investing in research and development for more effective and better-tolerated medications for IOP reduction contribute significantly to market expansion. Additionally, increasing awareness about eye health, regular eye screenings, and efforts to improve access to treatments globally play a crucial role in driving growth within the Primary Open-angle Glaucoma market.
Reimbursement Scenario in Primary Open Angle Glaucoma (POAG)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current Primary Open Angle Glaucoma (POAG) market trends, we take KOLs and SMEs ' opinion working in the Primary Open Angle Glaucoma (POAG) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Primary Open Angle Glaucoma (POAG) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Primary Open Angle Glaucoma (POAG) by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Primary Open Angle Glaucoma (POAG), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Primary Open Angle Glaucoma (POAG) epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Primary Open Angle Glaucoma (POAG) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Primary Open Angle Glaucoma (POAG) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Primary Open Angle Glaucoma (POAG) market
Report Highlights
- In the coming years, the Primary Open Angle Glaucoma (POAG) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Primary Open Angle Glaucoma (POAG) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Primary Open Angle Glaucoma (POAG). The launch of emerging therapies will significantly impact the Primary Open Angle Glaucoma (POAG) market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Primary Open Angle Glaucoma (POAG)
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Primary Open Angle Glaucoma (POAG) Report Insights
- Primary Open Angle Glaucoma (POAG) Patient Population
- Primary Open Angle Glaucoma (POAG) Therapeutic Approaches
- Primary Open Angle Glaucoma (POAG) Pipeline Analysis
- Primary Open Angle Glaucoma (POAG) Market Size and Trends
- Primary Open Angle Glaucoma (POAG) Market Opportunities
- Impact of upcoming Primary Open Angle Glaucoma (POAG) Therapies
Primary Open Angle Glaucoma (POAG) Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Primary Open Angle Glaucoma (POAG) Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Primary Open Angle Glaucoma (POAG) Market
- Primary Open Angle Glaucoma (POAG) Drugs Uptake
Primary Open Angle Glaucoma (POAG) Report Assessment
- Current Primary Open Angle Glaucoma (POAG) Treatment Practices
- Unmet Needs in the Primary Open Angle Glaucoma (POAG) Market
- Primary Open Angle Glaucoma (POAG) Pipeline Product Profiles
- Primary Open Angle Glaucoma (POAG) Market Attractiveness
- Primary Open Angle Glaucoma (POAG) Market Drivers and Barriers
Key Questions
Market Insights:
- What was the Primary Open Angle Glaucoma (POAG) drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Primary Open Angle Glaucoma (POAG) total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Primary Open Angle Glaucoma (POAG) market size during the forecast period (2019-2032)?
- At what CAGR, the Primary Open Angle Glaucoma (POAG) market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the Primary Open Angle Glaucoma (POAG) market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Primary Open Angle Glaucoma (POAG) market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of the Primary Open Angle Glaucoma (POAG)?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Primary Open Angle Glaucoma (POAG) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Primary Open Angle Glaucoma (POAG) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Primary Open Angle Glaucoma (POAG)?
- Out of all 7MM countries, which country would have the highest prevalent population of Primary Open Angle Glaucoma (POAG) during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current options for the Primary Open Angle Glaucoma (POAG) treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Primary Open Angle Glaucoma (POAG) in the USA, Europe, and Japan?
- What are the Primary Open Angle Glaucoma (POAG) marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Primary Open Angle Glaucoma (POAG)?
- How many therapies are in-development by each company for Primary Open Angle Glaucoma (POAG) treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Primary Open Angle Glaucoma (POAG) treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Primary Open Angle Glaucoma (POAG) therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Primary Open Angle Glaucoma (POAG) and their status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Primary Open Angle Glaucoma (POAG)?
- What are the global historical and forecasted market of Primary Open Angle Glaucoma (POAG)?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the Primary Open Angle Glaucoma (POAG) market
- To understand the future market competition in the Primary Open Angle Glaucoma (POAG) market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Primary Open Angle Glaucoma (POAG) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Primary Open Angle Glaucoma (POAG) market
- To understand the future market competition in the Primary Open Angle Glaucoma (POAG) market
